Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05524532 · ClinicalTrials.gov registry record · Phase 3
Effects of Immulina TM Supplements With PASC Patients
A Phase 3 study, sponsored by University of Mississippi Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
NCT05524532 is a Phase 3 study that has completed, run by University of Mississippi Medical Center. The registered enrollment target is 101 participants.
The verdict
NCT05524532, a Phase 3 study, has completed, sponsored by University of Mississippi Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
Study Summary
This is a multi-site study that will try to determine the effects of Immulina ™, a natural dietary supplement, on blood chemicals associated with inflammation that are often increased in patients with long COVID (also called PASC).
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Immulina TM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2023-07-20 |
| Est. Completion | 2025-07-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05524532
The ClinicalTrials.gov registry entry for NCT05524532 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05524532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05524532 about?
NCT05524532 is a clinical study titled "Effects of Immulina TM Supplements With PASC Patients". This is a multi-site study that will try to determine the effects of Immulina ™, a natural dietary supplement, on blood chemicals associated with inflammation that are often increased in patients with long COVID (also called PASC).
What is the current status of trial NCT05524532?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2023-07-20. Estimated completion is 2025-07-29.
What interventions are being tested in trial NCT05524532?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Immulina TM (DRUG).
Who is sponsoring clinical trial NCT05524532?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.